KOD will service platform for epilepsy patients next year

Japanese company

Record seizure symptoms and medication history… platform for specialists also available

A platform for epilepsy patients and healthcare professionals will soon be launched in Korea.

 

Japan's Knock on the Door (KOD) announced in May that it has established its branch in Seoul and is preparing to launch the service next year.

 

KOD was established in Tokyo, Japan, in 2018 with the goal of "Realizing a society where patients with intractable diseases and their families can shine and always stay true to themselves.” Hiroomi Hayashi, Representative Director of KOD, said, “To achieve this goal, we provide a platform where we work with patients with intractable diseases and their families to improve their medical care, life, and quality of life.” Specifically, KOD has built a platform for Japanese patients with intractable epilepsy.

 

The platform includes "nanacara," an application that allows patients to record symptoms such as seizures and medication information, "nanacara for Dr.," which allows specialists to check the information recorded by patients and their families during medical visits, and "nana-medi," an online medical consultation and medication guidance service that allows patients to connect with specialists and pharmacists anywhere in the country.

 

Director Hayashi explained, "By leveraging our accumulated data and network of patients, families, and doctors that use Nanacara, we provide solutions to pharmaceutical companies to help improve the quality of medical care for intractable diseases.

 

We strive to create a society where high-quality medical care can be quickly accessed anywhere in Japan." Currently, there are approximately 1 million people with epilepsy in Japan.

 

Approximately 300,000 are intractable epilepsy patients and approximately 100,000 are pediatric intractable epilepsy patients.

 

There are about 900 epilepsy specialists in Japan, affiliated with 450 medical institutions.

 

Currently, about 30,000 people in Japan have downloaded and used Nanacara, mainly pediatric intractable epilepsy patients and their families.

 

This is around 30% of the affected patients in Japan.

 

In addition, 265 of the approximately 450 medical institutions with epilepsy specialists have adopted Nanacara for Dr., which represents a 60% share.

 

Director Hayashi said, “Through these platforms, we can now more easily and accurately measure the patients' seizure records and facilitate smoother communication with healthcare professionals in their institutions.

 

Many patients and their families have also gained physical and mental relief with the use of our platform.” KOD began communicating with epilepsy patients and families in Korea last year.

 

During the discussions, the company identified the need to document seizure records and rapid delivery of information amongst Korean patients as well.

 

To address the need, KOD established a branch office in Seoul in May and is preparing to launch the service in 2025.

 

In Korea, Nanacara will be rebranded as 'Borabora.’

Director Hayashi added, "We want to create an environment in Korea where more people can support people with epilepsy, and where people with epilepsy can live true to themselves.

 

We hope that many people in Korea will use the platform and contribute to establishing an environment where patients can continue living a rewarding and valuable life.” KOD also participated in the International Epilepsy Congress that was held in Seoul from the 21st to the 22nd and held a booth presentation for Nanacara.

 

During the exhibition, we received many opinions from Korean epileptologists.

 

Building on the input, we will begin preparations to make Nanacara for Dr.

 

available to Korean epileptologists as well.

 

"We will also actively promote cooperation with related pharmaceutical companies that develop and provide anti-epileptic drugs in Korea.

 

We hope our collective efforts will contribute to the development of medical care for epilepsy in Korea."